← Guides

How do you prepare an APQR or PQR faster?

By Savi C., Co-Founder · Published Nov 16, 2026

FDA annual product review and EU product quality review

FDA, 21 CFR 211.180(e)

Records kept so data can evaluate each product’s quality standards at least annually

EU GMP, Chapter 1 paragraphs 1.10 and 1.11

Regular periodic or rolling reviews, normally conducted and documented annually, taking previous reviews into account

FDA, 21 CFR 211.180(e)

Purpose: decide whether specifications or manufacturing or control procedures need to change

EU GMP, Chapter 1 paragraphs 1.10 and 1.11

Purpose: verify process consistency and the appropriateness of specifications, highlight trends and identify improvements

FDA, 21 CFR 211.180(e)

Written procedures must cover a review of a representative number of batches, approved or rejected

EU GMP, Chapter 1 paragraphs 1.10 and 1.11

Twelve minimum elements, from starting materials to contractual arrangements

FDA, 21 CFR 211.180(e)

Must cover complaints, recalls, returned or salvaged products and 211.192 investigations for each product

EU GMP, Chapter 1 paragraphs 1.10 and 1.11

Covers failed batches, significant deviations and CAPA effectiveness, changes, variations, stability, returns, complaints and recalls

FDA, 21 CFR 211.180(e)

No grouping provision in the regulation

EU GMP, Chapter 1 paragraphs 1.10 and 1.11

Reviews may be grouped by product type where scientifically justified

FDA, 21 CFR 211.180(e)

Applies to the manufacturer

EU GMP, Chapter 1 paragraphs 1.10 and 1.11

Manufacturer and, where different, the marketing authorisation holder evaluate the results, under a technical agreement

The EU minimum contents, paragraph 1.10

Materials and process

  • Starting and packaging materials, especially from new sources, including supply chain traceability of active substances
  • Critical in-process controls and finished product results
  • Qualification status of relevant equipment and utilities, such as HVAC, water and compressed gases

Failures, deviations and changes

  • All batches that failed specification and their investigation
  • All significant deviations or non-conformances, their investigations and the effectiveness of the CAPA taken
  • All changes to processes or analytical methods
  • The adequacy of previous product, process or equipment corrective actions

Regulatory, stability and market

  • Marketing authorisation variations submitted, granted or refused, including export-only dossiers
  • Stability monitoring results and any adverse trends
  • All quality-related returns, complaints and recalls and their investigations
  • Post-marketing commitments for new authorisations and variations
  • Contractual arrangements under Chapter 7, to confirm they are up to date

Where the time goes

The analysis in a product review is rarely the slow part. The slow part is assembly: building the list of batches made in the period, pulling in-process and release results out of batch records and laboratory systems, finding every deviation, change and complaint tied to the product, and reconciling the counts so that the numbers in one section agree with the numbers in another.

When that work starts after the period closes, every question about a batch means going back to a record that was reviewed months earlier. That is the step to move.

Ways to prepare it faster

Capture through the year

  • Record the data each review section needs at batch release, while the record is open and the reviewer knows it
  • Use one product and batch identifier across batch records, LIMS, deviations, change control and complaints
  • Use the rolling review Chapter 1 allows, adding batches and events as they close rather than at year end

Decide the method once

  • Fix in the procedure which parameters are trended, how, and what counts as an adverse trend
  • Build one template that maps each section to both 211.180(e) and the twelve Chapter 1 elements where both apply
  • Group products by type only where scientifically justified, and record the justification
  • Agree responsibilities with the marketing authorisation holder in the technical agreement before the period starts

Close the loop

  • Carry forward the actions from the previous review and report on each one
  • Assess whether CAPA or revalidation is needed, as paragraph 1.11 requires, and track those actions under the quality system

The draft Chapter 1 revision

A revised Chapter 1, prepared by the EMA GMDP inspectors working group with PIC/S, went to stakeholder consultation in 2025, with comments due by December 3, 2025. It is a draft and not in force. As summarised by the ECA, it would clarify product grouping, reviews of products with only a few batches or none in the period, and when review timeframes can be adjusted with justification.

How Litewave fits

A product review summarises a year of batch records, so it is only as quick as the records are to read. Litewave reads paper or electronic records, checks every entry against your master record and specifications, and shows QA only the exceptions, each linked to the page it came from. When that happens at release, the exceptions for the year already exist, traceable to their source, before the review begins. Litewave proposes, qualified people approve.

Questions we get asked

Is an APR the same as a PQR?

They overlap but are not identical. The FDA annual product review under 211.180(e) focuses on whether specifications or procedures need to change. The EU product quality review under Chapter 1 has a longer minimum list, including starting materials, variations, equipment qualification and contracts. Many manufacturers write one report designed to satisfy both.

Does an API manufacturer need a product quality review?

Yes, under ICH Q7 section 2.5, which expects regular quality reviews of APIs, normally annual, covering critical in-process and API test results, failed batches, investigations, changes, stability, returns, complaints and recalls, and the adequacy of corrective actions.

Can the review be done on a rolling basis?

EU GMP Chapter 1 explicitly allows regular periodic or rolling reviews. FDA’s regulation requires evaluation at least annually and does not prescribe how the work is scheduled within the year.

Sources

  1. 21 CFR 211.180, General requirements for records and reports (eCFR)
  2. EudraLex Volume 4, EU GMP Chapter 1, Pharmaceutical Quality System
  3. ICH Q7, Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients
  4. ECA Academy, Revision of EU-GMP Chapter 1 planned with Consultation Phase